{"id":{"repo_id":"uwo","oai_identifier":"oai:uwo.scholaris.ca:20.500.14721/39879"},"canonical_url":"https://search.dev.ndltd.org/etd/uwo/oai:uwo.scholaris.ca:20.500.14721/39879","repository":{"repo_id":"uwo","name":"Western University","base_url":"https://uwo.scholaris.ca/server/oai/request"},"display":{"title":"The Effectiveness of Beta-blockers after Myocardial Infarction in Patients with Type 2 Diabetes","abstract":"Beta-blocker therapy reduces mortality and reinfarction after myocardial infarction (MI), but randomized triais have not included subjects with diabetes as a primary subgroup of interest. A retrospective cohort study was conducted using the Saskatchewan Health Databases to determine the effects of beta-blockers after MI in patients with type 2 diabetes, under real-world conditions. New users of antidiabetic agents with MI were identified by prescription records and ICD-9 codes. Drug exposures were determined from prescription records. Hospitalizations and deaths were documented over 9 years. Re-hospitalization after MI was studied as a measure of safety. Beta-blockers were associated with improved survival on univariate but not multivariate analysis, after controlling for clinical characteristics and medications. Recurrent MI and re-hospitalization were not increased in the betablocker group compared to controls. Beta-blocker therapy post-MI was not independently associated with a reduction in mortality in type 2 diabetes, after adjusting for interventions that reduce cardiovascular risk.","abstract_html":"Beta-blocker therapy reduces mortality and reinfarction after myocardial infarction (MI), but randomized triais have not included subjects with diabetes as a primary subgroup of interest. A retrospective cohort study was conducted using the Saskatchewan Health Databases to determine the effects of beta-blockers after MI in patients with type 2 diabetes, under real-world conditions. New users of antidiabetic agents with MI were identified by prescription records and ICD-9 codes. Drug exposures were determined from prescription records. Hospitalizations and deaths were documented over 9 years. Re-hospitalization after MI was studied as a measure of safety. Beta-blockers were associated with improved survival on univariate but not multivariate analysis, after controlling for clinical characteristics and medications. Recurrent MI and re-hospitalization were not increased in the betablocker group compared to controls. Beta-blocker therapy post-MI was not independently associated with a reduction in mortality in type 2 diabetes, after adjusting for interventions that reduce cardiovascular risk.","abstract_has_math":false,"creators":["McDonald, Charlotte G."],"institution":"The University of Western Ontario","degree_name":"Master of Science","degree_level":null,"degree_discipline":"Epidemiology and Biostatistics","degree_department":null,"school":null,"contributors":[],"advisors":["Mahon, Jeff"],"committee_chairs":[],"committee_members":[],"year":2004,"date_issued":"2004","date_published":"2004","updated_at":"2026-07-27T21:56:01Z","subjects":["Diabetes mellitus","type ii","Myocardial infarction/drug therapy","Betablockers","adrenergic","Saskatchewan","Databases","Outcomes Research"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/20.500.14721/39879","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Mahon, Jeff"]},{"key":"dc:creator","label":"Author","values":["McDonald, Charlotte G."]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-06-05T18:57:46Z"]},{"key":"dc:date.issued","label":"Date","values":["2004"]},{"key":"dc:publisher","label":"Institution","values":["The University of Western Ontario"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Epidemiology and Biostatistics"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["The University of Western Ontario"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Diabetes mellitus","type ii","Myocardial infarction/drug therapy","Betablockers","adrenergic","Saskatchewan","Databases","Outcomes Research"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/20.500.14721/39879"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Beta-blocker therapy reduces mortality and reinfarction after myocardial infarction (MI), but randomized triais have not included subjects with diabetes as a primary subgroup of interest. A retrospective cohort study was conducted using the Saskatchewan Health Databases to determine the effects of beta-blockers after MI in patients with type 2 diabetes, under real-world conditions. New users of antidiabetic agents with MI were identified by prescription records and ICD-9 codes. Drug exposures were determined from prescription records. Hospitalizations and deaths were documented over 9 years. Re-hospitalization after MI was studied as a measure of safety. Beta-blockers were associated with improved survival on univariate but not multivariate analysis, after controlling for clinical characteristics and medications. Recurrent MI and re-hospitalization were not increased in the betablocker group compared to controls. Beta-blocker therapy post-MI was not independently associated with a reduction in mortality in type 2 diabetes, after adjusting for interventions that reduce cardiovascular risk."]},{"key":"dc:title","label":"Title","values":["The Effectiveness of Beta-blockers after Myocardial Infarction in Patients with Type 2 Diabetes"]}]}],"canonical_facts":{"dc:contributor.advisor":["Mahon, Jeff"],"dc:creator":["McDonald, Charlotte G."],"dc:date.accessioned":["2026-06-05T18:57:46Z"],"dc:date.issued":["2004"],"dc:description.abstract":["Beta-blocker therapy reduces mortality and reinfarction after myocardial infarction (MI), but randomized triais have not included subjects with diabetes as a primary subgroup of interest. A retrospective cohort study was conducted using the Saskatchewan Health Databases to determine the effects of beta-blockers after MI in patients with type 2 diabetes, under real-world conditions. New users of antidiabetic agents with MI were identified by prescription records and ICD-9 codes. Drug exposures were determined from prescription records. Hospitalizations and deaths were documented over 9 years. Re-hospitalization after MI was studied as a measure of safety. Beta-blockers were associated with improved survival on univariate but not multivariate analysis, after controlling for clinical characteristics and medications. Recurrent MI and re-hospitalization were not increased in the betablocker group compared to controls. Beta-blocker therapy post-MI was not independently associated with a reduction in mortality in type 2 diabetes, after adjusting for interventions that reduce cardiovascular risk."],"dc:identifier.uri":["https://hdl.handle.net/20.500.14721/39879"],"dc:language.iso":["en"],"dc:publisher":["The University of Western Ontario"],"dc:subject":["Diabetes mellitus","type ii","Myocardial infarction/drug therapy","Betablockers","adrenergic","Saskatchewan","Databases","Outcomes Research"],"dc:title":["The Effectiveness of Beta-blockers after Myocardial Infarction in Patients with Type 2 Diabetes"],"dc:type":["Thesis"],"thesis:degree_discipline":["Epidemiology and Biostatistics"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["The University of Western Ontario"]},"updated_at":"2026-07-27T21:56:01Z"}